Triathlon All-Polyethylene Tibia Outcomes Study (APT)
A Retrospectively Enrolled and Prospectively Followed, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon All-Polyethylene Tibia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sabrina Cristofaro
- Phone Number: 551-329-8665
- Email: sabrina.cristofaro@stryker.com
Study Contact Backup
- Name: Marissa Puccio
- Phone Number: 201-675-1416
- Email: marissa.puccio@stryker.com
Study Locations
-
-
Michigan
-
Lansing, Michigan, United States, 48910
- Michigan Orthopaedic Center
-
-
New York
-
Buffalo, New York, United States, 14203
- Kaleida Health, Department of Orthopaedic Surgery, Buffalo General Hospital
-
Syracuse, New York, United States, 13214
- Syracuse Orthopedic Specialists, PC
-
-
North Carolina
-
Durham, North Carolina, United States, 27703
- Duke University Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Department of Orthopaedic Surgery Cleveland Clinic
-
-
Texas
-
Austin, Texas, United States, 78712
- Musculoskeletal Institute, University of Texas Health Austin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusions:
- Patient underwent primary TKA and is currently implanted with the Triathlon All-Polyethylene Tibia as well as compatible Stryker femoral and patellar components with no pending revision or removal.
- Patient has signed an IRB-approved, study specific Informed Patient Consent Form.
- Patient is a male or non-pregnant female and is 18 years of age or older at the time of study device implantation.
- Patient is willing and able to comply with postoperative scheduled clinical and radiographic evaluations.
Exclusions:
- Patient had an active or suspected latent infection in or about the affected knee joint at time of study device implantation.
- Patient had distant foci of infection which could have caused hematogenous spread to the implant site at time of study device implantation.
- Patient was skeletally immature at time of study device implantation.
- Patient has a mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.
- Patient's bone stock was compromised by disease, infection, or prior implantation which cannot provide adequate support and/or fixation to the prosthesis.
- Patient had severe instability of the knee joint secondary to the absence of collateral ligament integrity and function.
- Patient was immunologically suppressed or receiving steroids in excess of normal physiological requirements at the time of surgery (e.g. > 30 days duration of treatment).
- Patient is a prisoner.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Triathlon All-Polyethylene Tibia Knee
All subjects enrolled will have received the Triathlon All-Polyethylene Tibia Knee device.
|
Triathlon All-Polyethylene Tibia Knee is an all polyethylene resurfacing knee device using either a condylar stabilizing (CS) and posterior stabilizing (PS) device.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Society Score (KSS) Function
Time Frame: 10-years postoperative
|
The Knee Society Clinical Rating System is comprised of two distinct sub-scores: one for pain, range of motion (ROM) and joint stability, and one for functional parameters.
Sub-scores range from a potential minimum score of 0 to a maximum score of 100 points.
Although the specific scores are not distinguished as "excellent," "good," "fair," or "poor," a higher value represents a better outcome postoperative.
|
10-years postoperative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Kaplan-Meier Survival Analysis
Time Frame: 10-years postoperative
|
To present 10-year Kaplan-Meier survival analysis for the Triathlon APT
|
10-years postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.